ReviewPituitary2018
Management of nonfunctioning pituitary tumors: radiotherapy.
Review in Pituitary, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.Pituitary · 2022Pooled it
- Trade-offs in proton and photon radiotherapy for pituitary adenomas.Physics and imaging in radiation oncology · 2026Article
- Radiotherapeutic Strategies and Advances in the Management of Pituitary Adenomas.Neuroendocrinology · 2026Review
- Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.BMC endocrine disorders · 2025Article
- Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol.Frontiers in oncology · 2025Article
- Neuro-ophthalmic evaluation and management of pituitary disease.Eye (London, England) · 2024Review
- Clinical features of pituitary carcinoma: analysis based on a case report and literature review.Frontiers in endocrinology · 2024Review
- Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.Journal of clinical medicine · 2023Review
- Article
- Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- High-Grade Ectopic Pituitary Adenoma within the Cerebellopontine Angle: A Case Report.Journal of neurological surgery reports · 2023Article
- Remission, complications, and overall survival in transsphenoidal pituitary surgery-a Swedish single-center experience of 578 patients.Acta neurochirurgica · 2023Article
- Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures.Yonsei medical journal · 2022Article
- Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?Radiation oncology (London, England) · 2022Article
- Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas.Neurosurgical review · 2022Article
- Epidemiology of Male Hypogonadism.Endocrinology and metabolism clinics of North America · 2022Review
- Pituitary carcinoma - case series and review of the literature.Frontiers in endocrinology · 2022Review
- Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.Acta neurochirurgica · 2021Review
- The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with aBMJ open · 2020Article
- Fertility issues in aggressive pituitary tumors.Reviews in endocrine & metabolic disorders · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
External beam radiotherapy (RT) is an essential part of the management of intracranial tumors and has been used in treating pituitary adenomas for more than five decades. It has been demonstrated that conventional RT for postoperative residual or progressive nonfunctioning pituitary adenomas (NFAs) present an excellent long-term local tumor control, although its use has been limited because of the potential late toxicity related to radiation treatments. Recent advances in radiation techniques have led to more accurate treatments, rendering obsolete many commonly held views of the "old" radiotherapy. New techniques include intensity modulated radiotherapy, volumetric-modulated arc therapy, and stereotactic techniques, either stereotactic radiosurgery or fractionated stereotactic radiotherapy. New techniques allow the delivering of higher radiation doses to the target with rapid dose fall-off in the surrounding normal tissues, and potentially limiting the long term toxicity of radiation. In this review, we present a critical analysis of the most recent available literature on the use of radiation in patients with NFAs, focusing particularly on the efficacy and safety of radiation stereotactic techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.